The Binder/O'Rourke Laboratory

Welcome to the Binder/O'Rourke Laboratory!  Located in Perelman South 8th Floor, alongside the Parker Institute for Cancer Immunotherapy, the Binder/O'Rourke Lab is dedicated to advancing treatment options for glioblastoma.

Glioblastoma (GBM), glioma grade IV, is a devastating cancer with an annual incidence of 3.19/100,000 individuals per year (~10,000) and a median survival of ~16 months following standard-of-care surgery, radiotherapy, and chemotherapy.  Few advances in treatment have been realized over the past 20 years, and 2-year survival remains close to 25%.  We are developing novel methods for treating GBM and improving the outcomes of patients with this devastating disease.  Our research focuses several areas of immuno-oncology, supported by model establishment and development.  Dr. O'Rourke's position in the University of Pennsylvania Brain and Spinal Cord Tumor Program provides our group with access to significant tumor tissue resources, providing a wide variety of GBM models for our research.

The Binder/O'Rourke Lab is proud to be participating members of the Center for Cellular Immunotherapies (CCI) at Penn, as well as the GBM Translational Center of Excellence (GBM TCE) and the Department of Neurosurgery within the Perelman School of Medicine. 

Our clinical team has multiple ongoing clinical trials for GBM.  For clinical questions, please call 215-662-3487.

For information on GBM TCE activities, contact Zev Binder.